Systematic LC‐MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought‐out chromatography

AhnoffM WurzerA LindmarkBandJussilaR.Characterisation of serum albumin and lysoPCs as major contributors to plasma sample matrix effects on electrospray ionisation efficiency.51st ASMS Conference on Mass Spectrometry Montreal Canada 2003.

AurandC TrinhA BrAndesHK BellDSandYeM.Increased bioanalytical throughput using selective phospholipid depletion.57th ASMS Conference on Mass Spectrometry Philadelphia PA 2009.

10.1002/(SICI)1097-0231(19990830)13:16<1657::AID-RCM694>3.0.CO;2-L

BennettPKandVan HorneKC.Identification of the major endogenous and persistent compounds in plasma serum and tissue that cause matrix effects with electrospray LC/MS techniques.American Association of Pharmaceutical Scientists Annual Meeting and Exposition Salt Lake City UT 2003.

BergeronM LahaieM FurtadoMandGarofoloF.Selection of buffer additives for liquid–liquid extraction (LLE) procedure to remove matrix effect due to phospholipids in LC‐MS/MS.57th ASMS Conference on Mass Spectrometry Philadelphia PA 2009.

10.1016/j.aca.2003.12.023

10.1016/j.jpba.2008.12.039

10.1021/ac9001244

10.1002/rcm.1923

10.1016/j.chroma.2008.11.101

10.1016/S0021-9673(03)00393-5

10.1208/s12248-009-9100-9

10.1016/j.jpba.2009.08.003

10.1016/j.jchromb.2007.04.009

Food and Drug Administration, 2001, Guidance for Industry: Bioanalytical Method Validation, 1

GarofoloF MessJ‐CandCoteCS.Guidelines for method development of HILIC‐LC‐MS/MS: choice of columns and chromatographic conditions to handle matrix effect due tphopholipids.American Association of Pharmaceutical Scientists Annual Meeting and Exposition Atlanta GA 2008.

10.1002/rcm.3333

10.1016/j.chroma.2009.02.032

10.1016/j.jchromb.2007.03.017

10.1002/1099-0801(200010)14:6<422::AID-BMC25>3.0.CO;2-I

Jemal M, 2005, Identification and Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC‐MS

10.1002/1097-0231(20001015)14:19<1757::AID-RCM90>3.0.CO;2-C

10.1002/(SICI)1097-0231(19990130)13:2<97::AID-RCM461>3.0.CO;2-T

10.1016/S0731-7085(00)00245-4

10.2174/138920006777697927

10.1016/S0731-7085(00)00309-5

10.1002/rcm.757

10.1002/rcm.2016

10.1021/ac9708811

10.1016/j.chroma.2006.04.065

Lehninger AL, 1982, Principles of Biochemistry, 707

10.1016/j.jchromb.2006.02.011

10.1002/rcm.549

LiuG SnappHM JiQandArnoldME.Method Development of a UPLC Assay for the Bioanalysis of Ketoconazole in Human Plasma.57th ASMS Conference on Mass Spectrometry Philadelphia PA 2009.

10.1016/j.jpba.2005.07.028

10.1016/S0378-4347(98)00317-X

10.1002/jssc.200600526

10.1021/cr9900883

10.1016/j.jchromb.2003.08.026

Neue UD, 1997, HPLC columns: Theory, Technology, and Practice, 58

OuyangZ JemalMandShenX.Does LC column type/brand affect LC/MS response?53th ASMS Conference on Mass Spectrometry San Antonio TX 2005.

OuyangZ WuSandJemalM.Biological sample phospholipids clean up: A comparison of sample preparation techniques.57th ASMS Conference on Mass Spectrometry Philadelphia PA 2009.

10.1016/j.jchromb.2008.05.027

10.1016/j.chroma.2006.12.079

10.1016/j.chroma.2007.11.048

10.1002/bmc.563

10.1002/rcm.1277

10.1002/jssc.200600492

10.1016/S0021-9673(97)00376-2

10.1002/mas.10061

10.1021/ac9911692

SchoenerDandMurakamiS.The use of liquid–liquid extraction along with colloidal silica and polyvalent cations to remove phospholipids that produce ESI matrix effects.57th ASMS Conference on Mass Spectrometry Philadelphia PA 2009.

10.1016/j.jchromb.2006.04.022

Schwarz HP, 1977, Phospholipid composition of blood plasma, erythrocytes, and ‘ghosts’ in sickle cell disease, Clinical Chemistry, 23, 1548, 10.1093/clinchem/23.9.1548

10.1097/00007691-200302000-00001

10.1016/j.jchromb.2003.11.043

10.1016/j.jpba.2006.06.018

10.1016/j.jchromb.2005.06.005

10.1016/j.jchromb.2006.03.006

10.1002/chir.530050302

10.1007/s00216-003-2146-0

10.1016/S0378-4347(01)00188-8

10.1016/j.jpba.2006.01.006

10.1016/j.jpba.2006.01.002

Van HorneKCandBennettPK.Preventing matrix effects by using new sorbents to remove phospholipids from biological samples.American Association of Pharmaceutical Scientists Annual Meeting and Exposition Salt Lake City Utah 2003.

10.1208/aapsj0901004

10.1016/j.aca.2004.07.065

10.1016/S1570-0232(03)00572-5

WilliamsL LindenmuthM JonesR DesbrowC CaulfieldJ DowthwaiteG CalverleyR JordanSandLodderH.Phospholipid removal: a comparison between traditional liquid–liquid extraction (LLE) and supported liquid extraction (SLE) using LC‐MS/MS analysis.57th ASMS Conference on Mass Spectrometry Philadelphia PA 2009.

10.1023/A:1018978602141

10.1002/rcm.3680

10.1002/rcm.4228

XiaY‐QandJemalM.Evaluation of UHPLC column efficiency at different flow rates and retention factors: implications of the not‐so‐expected results.56th ASMS Conference on Mass Spectrometry Denver CO 2008.

10.1021/ac9012336

10.1002/rcm.4121

10.1002/(SICI)1097-0231(19990815)13:15<1611::AID-RCM683>3.0.CO;2-C

10.1002/rcm.2517

XiaY‐Q OuyangZandJemalM.Automated column/mobile phase screening system to achieve optimum chromatographic separation and sensitivity during LC‐MS/MS bioanalytical method development.54th ASMS Conference on Mass Spectrometry Seattle WA 2006b.

10.1016/j.jpba.2007.02.006

10.1002/rcm.2502

10.1002/rcm.3339

YongB HudsonW JonesDandChenY‐L.A simple way to remove phospholipids from bioanalytical samples.57th ASMS Conference on Mass Spectrometry Philadelphia PA 2009.

10.1016/j.japna.2003.08.016

10.1016/j.chroma.2009.03.071